EXHIBIT 99.2 ================================================================== ============== LOAN AND SECURITY AGREEMENTLoan and Security Agreement • April 12th, 1999 • Number Nine Visual Technology Corp • Computer peripheral equipment, nec • Massachusetts
COMMON STOCKUnderwriting Agreement • October 4th, 1999 • Exactis Com Inc • Telegraph & other message communications • New York
Blueprint Medicines Corporation Common Stock, $0.001 par value Underwriting AgreementUnderwriting Agreement • December 13th, 2017 • Blueprint Medicines Corp • Pharmaceutical preparations • New York
Blueprint Medicines Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 3,703,704 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 555,555 additional shares (the “Optional Shares”) of Common Stock, par value $0.001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
EXHIBIT 4.1 ------------------------------------------------------------------- ------------- CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENTConvertible Preferred Stock Purchase Agreement • April 12th, 1999 • Number Nine Visual Technology Corp • Computer peripheral equipment, nec • New York
EXHIBIT 1.1 _____________ Shares INTERTRUST TECHNOLOGIES CORPORATION Common Stock, $0.001 par value UNDERWRITING AGREEMENT ----------------------Underwriting Agreement • April 6th, 2000 • Intertrust Technologies Corp • Services-computer programming services • New York
Exhibit 10.32 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. LICENSE AND ASSIGNMENT AGREEMENTLicense and Assignment Agreement • March 30th, 2000 • Sepracor Inc /De/ • Pharmaceutical preparations • Delaware
CAMBRIDGE DISPLAY TECHNOLOGY, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • December 15th, 2004 • Cambridge Display Technology, Inc. • Semiconductors & related devices • New York
FLUIDIGM CORPORATION SERIES E PREFERRED STOCK PURCHASE AGREEMENT First Closing: June 13, 2006 Second Closing: December 22, 2006 Third Closing: March 30, 2007 Fourth Extended Closing: October 10, 2007 Fifth Extended Closing: October 26, 2007 Sixth...Series E Preferred Stock Purchase Agreement • September 18th, 2008 • Fluidigm Corp • Laboratory analytical instruments • California
THIS SERIES E PREFERRED STOCK PURCHASE AGREEMENT is made as of June 13, 2006, by and among Fluidigm Corporation, a California corporation (the “Company”), and the purchasers listed on the Schedule of Purchasers attached hereto as EXHIBIT A (the “Schedule of Purchasers”). The persons or entities listed thereon are hereinafter referred to collectively as the “Purchasers” and individually as a “Purchaser.”
AMENDMENT TO MENON- CELLCEUTIX AGREEMENT WITHOUT CHANGING THE TOTAL AMOUNT OF ROYALTIES PAYABLE UNDER THE TERMS OF THE PRIOR AGREEMENTMenon-Cellceutix Agreement • September 2nd, 2014 • Cellceutix CORP • Pharmaceutical preparations • Massachusetts
This Amendment, effective on signature of the last party to sign (“Effective Date”), between Dr. Krishna Menon, (hereinafter “Menon”) and Cellceutix Corporation, a Nevada corporation located at 100 Cummings Center, Suite 151, Beverly MA 01915 USA (hereinafter “Cellceutix”), amends a prior agreement between these parties dated October 17, 2007 (“Prior Agreement” Attachment A hereto), by which Menon assigned to Cellceutix all right, title and interest to a Compound (as defined therein) and patents thereon in consideration for a percentage of Net Sales of the Compound, also known as Kevetrin.
SECOND AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • August 8th, 2019 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS SECOND AMENDED AND RESTATED LICENSE AGREEMENT (this “Agreement”), effective as of this 17th day of April, 2019 (the “Second Amendment Effective Date”), by and between Panion & BF Biotech, Inc., with offices at 16F No. 3, Yuanqu Street, Nangang District, Taipei, Taiwan, ROC (hereinafter “Licensor”), and Akebia Therapeutics, Inc., with offices at 245 First Street, Cambridge, MA as successor-in-interest to Keryx Biopharmaceuticals, Inc. (hereinafter “Licensee”).
SETTLEMENT AGREEMENTSettlement Agreement • April 1st, 2015 • Massachusetts
THIS SETTLEMENT AGREEMENT (the “Settlement Agreement”) is made and entered into on April 1, 2015, by and between defendants Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc. (collectively, “Teva”), and United Food and Commercial Workers Unions and Employers Midwest Health Benefits Fund, Allied Services Division Welfare Fund, Fraternal Order of Police Miami Lodge 20 Insurance Trust Fund, New York Hotel Trades Council & Hotel Assoc. of New York City, Inc. Health Benefits Fund, Laborers International Union of North America Local 35 Health Care Fund, International Brotherhood of Electrical Workers Local 595 Health and Welfare Fund, Laborers International Union of North America Local 17 Health Care Fund, International Union of Machinists and Aerospace Workers District No. 15 Health Fund, Michigan Regional Council of Carpenters Employee Benefits Fund, and
FLUIDIGM CORPORATION EIGHTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT June 13, 2006Investor Rights Agreement • April 14th, 2008 • Fluidigm Corp • California
THIS EIGHTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of June 13, 2006 by and among Fluidigm Corporation, a California corporation (the “Company”), the persons set forth on EXHIBIT A hereto (the “New Investors”), the persons set forth on the Schedule of Founders attached hereto as EXHIBIT B (the “Founders”), and the persons set forth on EXHIBIT C hereto (the “Prior Investors”). The Prior Investors and the New Investors are referred to herein collectively as the “Investors.”
Licensing with U.S. EntitiesLicensing Agreement • May 13th, 2008
ASSET PURCHASE AGREEMENT dated as of November 26, 2012 among ADGERO BIOPHARMACEUTICALS, INC. as Buyer, and ST. CLOUD INVESTMENTS, LLC, as Seller.Asset Purchase Agreement • February 14th, 2017 • Adgero Biopharmaceuticals Holdings, Inc. • Pharmaceutical preparations • New York
Licensing with U.S. EntitiesLicensing Agreement • November 4th, 2011
FLUIDIGM CORPORATION SERIES E PREFERRED STOCK PURCHASE AGREEMENT First Closing: June 13, 2006 Second Closing: December 22, 2006 Third Closing: March 30, 2007 Fourth Extended Closing: October 10, 2007 Fifth Extended Closing: October 26, 2007 Sixth...Series E Preferred Stock Purchase Agreement • September 15th, 2008 • Fluidigm Corp • Laboratory analytical instruments • California
THIS SERIES E PREFERRED STOCK PURCHASE AGREEMENT is made as of June 13, 2006, by and among Fluidigm Corporation, a California corporation (the “Company”), and the purchasers listed on the Schedule of Purchasers attached hereto as EXHIBIT A (the “Schedule of Purchasers”). The persons or entities listed thereon are hereinafter referred to collectively as the “Purchasers” and individually as a “Purchaser.”
AGREEMENTAgreement • September 2nd, 2014 • Cellceutix CORP • Pharmaceutical preparations • Massachusetts
IN THIS AGREEMENT, Cellceutix Corporation, a Nevada corporation (“Cellceutix”), and Wayne O. Aruda, (“Aruda”), Aruda Inc. dba Agrenetics, a Massachusetts corporation (“Agrenetics”), (each of Cellceutix, Aruda, and Agrenetics being a “Party”), agree as follows:
Stanford Law School Supreme Court Litigation Clinic Moot Court Program Student Observer AgreementStudent Observer Agreement • May 5th, 2020
Welcome to the Stanford Law School Supreme Court Litigation Clinic and Center for Internet and Society! We are glad to invite you to join us for our upcoming moot of Lawrence Golan, et al., v. Eric Holder, Jr., et al., 10-‐545 conducted on behalf of attorney Anthony Falzone (CIS, Fair Use Project), counsel for Petitioners. The moot court will be held on Friday, September 30 at 2:00pm in the moot courtroom located in Room B80 of the law school academic building.
FLUIDIGM CORPORATION SERIES E PREFERRED STOCK PURCHASE AGREEMENT First Closing: June 13, 2006 Second Closing: December 22, 2006 Third Closing: March 30, 2007 Fourth Extended Closing: October 10, 2007 Fifth Extended Closing: October 26, 2007 Sixth...Series E Preferred Stock Purchase Agreement • September 22nd, 2008 • Fluidigm Corp • Laboratory analytical instruments • California
THIS SERIES E PREFERRED STOCK PURCHASE AGREEMENT is made as of June 13, 2006, by and among Fluidigm Corporation, a California corporation (the “Company”), and the purchasers listed on the Schedule of Purchasers attached hereto as EXHIBIT A (the “Schedule of Purchasers”). The persons or entities listed thereon are hereinafter referred to collectively as the “Purchasers” and individually as a “Purchaser.”
